Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-507 · 6 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | MEDI-507 |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | MEDI-507 |
| 4 | ACTIVE_COMPARATOR | MEDI-507 |
| 5 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MEDI-507 | DRUG | Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody) |
| Placebo | OTHER | - |
Inclusion Criteria: * Plaque psoriasis involving at least 10% of body surface area * Age 18 through 65 years at the time of the first dose of study drug * Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have u...
MEDI-507 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN). It has been studied in clinical trials for graft versus host disease, kidney diseases, cancer, plaque psoriasis, and psoriasis. It is in Phase 1 development and is not described as approved for any indication.
MEDI-507 has been studied for graft versus host disease, including steroid-resistant acute GvHD and at least Grade II GvHD, as well as for prevention of acute renal allograft rejection in kidney disease. Trials have also listed cancer, plaque psoriasis, and psoriasis among the conditions studied.
MEDI-507 is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is the sponsor associated with the clinical trial program for this asset.
MEDI-507 is in Phase 1 clinical development. Its trials are listed as Phase 1 studies, and the program includes completed trials only, with no active trials currently listed. It is investigational and has not been described as FDA approved.
MEDI-507 has been evaluated in completed Phase 1 trials including NCT00813618 in pediatric patients with graft versus host disease, NCT00807794 in kidney disease for prevention of acute renal allograft rejection, NCT00806728 in steroid-resistant acute GvHD, and NCT00806208 in at least Grade II GvHD.
The MEDI-507 clinical program lists a total enrollment of 420 patients across its trials. Individual completed Phase 1 studies ranged from 10 patients in the pediatric GvHD trial to 34 patients in the dose-escalation GvHD trial, with trials conducted in the United States.